Endexx Corp announced that it has secured three key significant orders for its newly acquired, non-nicotine plant-based vape product, HYLA, which will generate a combined $2.3 million in revenue for the company during its first two fiscal quarters of 2023.
The developer and distributor of all-natural, plant-derived topical skincare products said the orders came from distributors in the western region in the US, a central Asian nation and Dubai in the UAE, with the Dubai order extending over six months with potential for accelerated growth.
“This first set of orders puts us on track to recoup the investment made to acquire HYLA by the second quarter of this year, and to significantly increase our overall revenue intake,” Endexx CEO Todd Davis said in a statement.
READ: Endexx achieves distribution registration for its hemp and CBD products in 4 key US states
“Combined with both our CBD pain and men’s skincare products and non-CBD skincare line, we believe we are creating an important niche franchise that will appeal to an increasingly wider audience worldwide,” Davis added.
Through its operating division CBD Unlimited, Endexx develops and distributes all-natural CBD products derived from cannabis sativa plants containing less than 0.1% THC. Its products include oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief.
Contact Sean at sean@proactiveinvestors.com